The 2024 European guideline on the management of epididymo-orchitis
Justice, Edwin D Fricker, John Ross, Jonathan D C Kopa, Zsolt Skerlev, Mihael Patel, Rajul
Justice, Edwin D
Fricker, John
Ross, Jonathan D C
Kopa, Zsolt
Skerlev, Mihael
Patel, Rajul
Affiliation
The Royal Wolverhampton NHS Trust; Hampshire and Isle of Wight NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; Semmelweis University; Zagreb University School of Medicine; University of Southampton
Other Contributors
Publication date
2025-07-23
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
The European guideline on the management of epididymo-orchitis has been updated in 2024. This guideline offers advice on the diagnosis, investigation, treatment and follow-up for the management of epididymo-orchitis. For treatment of patients with a history suggestive of sexually transmitted pathogens-ceftriaxone dose increased to 1 g intramuscularly (IM) single dose alongside doxycycline. The use of dual therapy with azithromycin is no longer recommended, unless cefixime is being given as an alternative to ceftriaxone. For treatment of patients with a history including risks for both sexually transmitted and enteric pathogens-ceftriaxone IM single dose and either ofloxacin or levofloxacin is recommended. Where enteric pathogens are suspected as the likely cause, either ofloxacin or levofloxacin is recommended as monotherapy. This guideline covers a range of clinical scenarios, including rarer and non-sexually transmitted causative agents.
Citation
Justice ED, Fricker J, Ross JDC, Kopa Z, Skerlev M, Patel R. The 2024 European guideline on the management of epididymo-orchitis. J Eur Acad Dermatol Venereol. 2025 Jul 23. doi: 10.1111/jdv.20865. Epub ahead of print.
Type
Article